Analyst firms · Citigroup · CRL
Citigroup CRL price target and rating history
Charles River Laboratories International Inc. (CRL) · Health Care
Citigroup rates Charles River Laboratories International Inc. (CRL) Buy with a $200 price target, as of its latest action on Jul 9, 2025. It has published 5 rating actions on CRL since February 2022, including 3 upgrades and 2 downgrades. Across 5 firms with a CRL price target in the last 12 months, the median target is $220.
- Current rating
- Buy
- Price target
- $200
- Median target, all firms
- $220
- Actions on CRL
- 5
Citigroup price target on CRL
Every Citigroup rating on CRL
- Jul 9, 2025
- Mar 4, 2025
- Oct 1, 2024
- Jul 10, 2023
- Feb 17, 2022
How other firms rate CRL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $357 | Sep 30, 2026 |
| CLSA | Hold | $219 | Jul 20, 2026 |
| Morgan Stanley | Overweight | $220 | Jun 17, 2026 |
| RBC Capital Markets | Outperform | $215 | Apr 14, 2026 |
| BofA Securities | Buy | $225 | Dec 15, 2025 |
| Argus Research | Buy | Nov 17, 2025 |
Questions about Citigroup and CRL
- What is Citigroup's price target for CRL?
- Citigroup's latest stated price target for Charles River Laboratories International Inc. (CRL) is $200, from its action on Jul 9, 2025.
- What is Citigroup's rating on CRL?
- Citigroup rates CRL Buy, a bullish rating, as of Jul 9, 2025.
- When did Citigroup last change its view on CRL?
- On Jul 9, 2025, Citigroup upgrades to Buy from Neutral, price target $200.
- How does Citigroup's CRL target compare with other analysts?
- Across 5 firms with a CRL price target in the last 12 months, the median target is $220.
More CRL rating histories
All Citigroup ratingsCRL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.